ArticleFrontiers in cardiovascular medicine2025
Nonlinear association between triglyceride-glucose index and risk of hyperuricemia in early-stage cardiovascular-kidney-metabolic syndrome: a cross-sectional study of United States population.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integration of triglyceride-glucose index and biological aging to predict cardiovascular disease risk in cardiovascular-kidney-metabolic syndrome stages 0-3: a multiple prospective cohort study.Cardiovascular diabetology · 2026Article
- Article
- Association between the triglyceride-glucose index and hyperuricemia in an apparently healthy population with zero metabolic syndrome components: a cross-sectional study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cardiovascular-kidney-metabolic (CKM) syndrome represents a critical intersection of cardiovascular, renal, and metabolic disorders, emphasizing the importance of early risk stratification and intervention. The triglyceride-glucose (TyG) index, a surrogate marker of insulin resistance, has shown promise in predicting cardiometabolic risk. However, its association with hyperuricemia in early-stage CKM syndrome remains uncertain. Methods: This study analyzed data from 14,716 adult participants in the NHANES 2005-2018 dataset. A complex survey weight design and multiple imputation techniques were utilized to address missing data. The relationship between the TyG index and hyperuricemia was examined using generalized additive models and piecewise regression, with multivariable logistic regression adjusting for 14 potential confounders. Results: The TyG index demonstrated a significant positive association with hyperuricemia. Each unit increase in the TyG index was associated with a 62% higher risk of hyperuricemia (OR = 1.62, 95% CI: 1.45-1.81). A non-linear relationship was identified, with an inflection point at a TyG index of 9.50. Below this threshold, higher TyG index values were significantly associated with increased odds of hyperuricemia (OR = 2.18, 95% CI: 1.82-2.61), while above the threshold, the association became non-significant (OR = 0.79, 95% CI: 0.57-1.10). Subgroup analyses confirmed consistent associations across various demographic and clinical characteristics. Conclusions: The TyG index may serve as a valuable biomarker for identifying hyperuricemia risk in individuals with early-stage CKM syndrome, offering potential utility in clinical and public health settings. Further longitudinal studies are warranted to confirm these findings and assess the impact of TyG index-guided interventions on CKM syndrome progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.